Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2013

View Archived Issues

Consortium developing placental malaria vaccine receives E.U. grant

Dr. Reddy's Laboratories presents new series of CETP inhibitors

Glenmark Pharmaceuticals presents new ITK/TSK inhibitors

Alzheimer's Drug Discovery Foundation awards grant for novel peptide research

HUYA Bioscience enters collaboration with Zhangjiang Biotech Pharmaceutical Base

Senesco takes steps to accelerate enrollment in phase Ib/IIa study of anticancer candidate

SynapDx and Illumina join to develop early detection tools for autism

Galapagos achieves milestones in Servier alliances

Pfizer presents promising phase IIa results for topical tofacitinib in plaque psoriasis

Phase II study of palifosfamide in incurable germ cell tumors begins

First patient enrolled in third phase III study of laquinimod in multiple sclerosis

Novogen signs memorandum of understanding with The Ingham Institute

VAC-3S immunotherapeutic proves safe and well tolerated in HIV-1

Cylene and TetraGene enter exclusive worldwide agreement for anticancer candidate

Genentech presents phase I results for GDC-0068

Second Sight's Argus II Retinal Prosthesis implanted in first patients in the Middle East

KM-023 demonstrates good tolerance and pharmacokinetics in a phase I trial

Athera Biotechnologies and Dyax patent novel antibodies

Gervais Danone discloses new bacterial strains for infections

Researchers at Two to Biotech divulge new peptides

Maximum tolerated dose defined in CH-5132799 study

Japanese launch of Cimzia for rheumatoid arthritis

GSK files for European approval of albiglutide

Janssen files MAA for fixed-dose combination of canagliflozin and metformin

DSP and Nippon Shinyaku sign Japanese agreement for SMP-986

U.K. approval for Duexis for osteoarthritis, rheumatoid arthritis and ankylosing spondylitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...